cancer patients irrespective of drug is identified. The estimate combines the prediction of number of newly diagnosed and treated patients with the prediction of number of patients who were diagnosed previously and would probably be treated in a given year due to a relapse or progression of the primary malignant disease. In the second step, the number is adjusted to individual usage of drugs according to treatment scheme assumed by the panel of experts, adjusted using information from clinical registries. RESULTS: The model currently provides predictions of potentially treated patients with quantified uncertainties. Regarding the most common targeted anticancer therapies, follow-
ing numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving bevacizumab for colorectal cancer, 301 (151; 449) patients receiving cetuximab for colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number of patients requiring targeted anticancer therapy in the years to come. Final outcome is used by decision makers for planning of health care expenses in the Czech Republic.

De Cambra S1, Mladisi D2, Neale S3, Faulkner EC2

ANALYSIS BASED ON A STUDY OF CURRENT REIMBURSEMENT

REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN NURSING SIBLINGS WITH SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY

Roesyr H1, Boschhoff HG2, Vergnagora A1, Choudry C3, Walser S

AIM: G-AM: Assessment-in-Nursing, Schopfheim, Germany, 3TheraLink Heidelberg, Heidelberg. METHODS: We compared rates for individual anthracycline drugs according to reimbursement schemes validated by the panel of experts, adjusted using information from clinical registries. RESULTS: The model currently provides predictions of potentially treated patients with quantified uncertainties. Regarding the most common targeted anticancer therapies, follow-
ing numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving bevacizumab for colorectal cancer, 301 (151; 449) patients receiving cetuximab for colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number of patients requiring targeted anticancer therapy in the years to come. Final outcome is used by decision makers for planning of health care expenses in the Czech Republic.

Roesyr H1, Boschhoff HG2, Vergnagora A1, Choudry C3, Walser S

APh GmbH Assessment-in-Nursing, Schopfheim, Germany, 3TheraLink Heidelberg, Heidelberg. METHODS: We compared rates for individual anthracycline drugs according to reimbursement schemes validated by the panel of experts, adjusted using information from clinical registries. RESULTS: The model currently provides predictions of potentially treated patients with quantified uncertainties. Regarding the most common targeted anticancer therapies, follow-
ing numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving bevacizumab for colorectal cancer, 301 (151; 449) patients receiving cetuximab for colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number of patients requiring targeted anticancer therapy in the years to come. Final outcome is used by decision makers for planning of health care expenses in the Czech Republic.

Roesyr H1, Boschhoff HG2, Vergnagora A1, Choudry C3, Walser S

APh GmbH Assessment-in-Nursing, Schopfheim, Germany, 3TheraLink Heidelberg, Heidelberg. METHODS: We compared rates for individual anthracycline drugs according to reimbursement schemes validated by the panel of experts, adjusted using information from clinical registries. RESULTS: The model currently provides predictions of potentially treated patients with quantified uncertainties. Regarding the most common targeted anticancer therapies, follow-
ing numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving bevacizumab for colorectal cancer, 301 (151; 449) patients receiving cetuximab for colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number of patients requiring targeted anticancer therapy in the years to come. Final outcome is used by decision makers for planning of health care expenses in the Czech Republic.

Roesyr H1, Boschhoff HG2, Vergnagora A1, Choudry C3, Walser S

APh GmbH Assessment-in-Nursing, Schopfheim, Germany, 3TheraLink Heidelberg, Heidelberg. METHODS: We compared rates for individual anthracycline drugs according to reimbursement schemes validated by the panel of experts, adjusted using information from clinical registries. RESULTS: The model currently provides predictions of potentially treated patients with quantified uncertainties. Regarding the most common targeted anticancer therapies, follow-
ing numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving bevacizumab for colorectal cancer, 301 (151; 449) patients receiving cetuximab for colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number of patients requiring targeted anticancer therapy in the years to come. Final outcome is used by decision makers for planning of health care expenses in the Czech Republic.

Roesyr H1, Boschhoff HG2, Vergnagora A1, Choudry C3, Walser S

APh GmbH Assessment-in-Nursing, Schopfheim, Germany, 3TheraLink Heidelberg, Heidelberg. METHODS: We compared rates for individual anthracycline drugs according to reimbursement schemes validated by the panel of experts, adjusted using information from clinical registries. RESULTS: The model currently provides predictions of potentially treated patients with quantified uncertainties. Regarding the most common targeted anticancer therapies, follow-
ing numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving bevacizumab for colorectal cancer, 301 (151; 449) patients receiving cetuximab for colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number of patients requiring targeted anticancer therapy in the years to come. Final outcome is used by decision makers for planning of health care expenses in the Czech Republic.